Clinical Trial Update: ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial ENX-102 as monotherapy for generalized anxiety disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• ENX-102

Snippet

Sponsor: Engrail Therapeutics INC | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: COMPLETED